I still believe the PR was issued at Donohoe's recommendation. NGIO shares are still contingent upon uplisting to NASDAQ. With the 1:1 dividend also contingent upon uplisting there is too much uncertainty. Worst case scenario, you don't get either if uplisting fails. If uplisting is delayed, so are two dividends. Too much pie in the sky for NASDAQ, imo. Now the 1:1 dividend has been clarified.
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links